Seho Park

Dr. Seho Park

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SPSeho Park
Seho Park
Ja Seung KooJa Seung Koo
Ja Seung Koo
HPHyung Seok Park
Hyung Seok Park
JKJ.-H. Kim
J.-H. Kim
SCS.-Y. Choi
S.-Y. Choi
KLK. S. Lee
K. S. Lee
Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ≥10% nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. Results: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.

1 February 2012 in The Breast
Verified
Journal Article
Open access
SPSeho Park
Seho Park
Ja Seung KooJa Seung Koo
Ja Seung Koo
MKMin Suk Kim
Min Suk Kim
HPHyung Seok Park
Hyung Seok Park
JLJun Sang Lee
Jun Sang Lee
BPByeong-Woo Park
Byeong-Woo Park
To investigate the significance of immunohistochemical molecular subtyping, we evaluated outcomes of subtypes based on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. Using tissue microarrays, 1006 breast cancer patients between November 1999 and August 2005 were categorized into four subtypes: luminal A (ER+ and/or PR+, HER2-, Ki-67 < 14%), luminal B (ER+ and/or PR+, HER2-, Ki-67 ≥ 14% or ER+ and/or PR+, HER2+), HER2-enriched (ER-, PR-, HER2+), and triple-negative breast cancer (TNBC) (ER-, PR-, HER2-). Demographics, recurrence patterns, and survival were retrospectively analyzed using uni-/multivariate analyses. Luminal A, luminal B, HER2-enriched, and TNBC accounted for 53.1%, 21.7%, 9.0%, and 16.2% of cases, respectively. Luminal A presented well-differentiation and more co-expression of hormone receptors comparing to luminal B. HER2-enriched showed larger size and higher nodal metastasis. TNBC demonstrated younger age at diagnosis, larger size, undifferentiation, higher proliferation, and frequent visceral metastases. The peak of recurrence for luminal A was at 36 months postoperatively, while that for HER2-enriched and TNBC peaked at 12 months. The relapse risk of luminal B was mixed. Luminal A showed the best survival, but no difference was observed between the other three subtypes. When matched by nodal status, however, TNBC showed the worst outcomes in node-positive patients. In multivariate analyses, luminal A remained a positive prognostic significance. Immunohistochemically-defined subtypes showed different features, recurrence patterns, and survival. Therefore, molecular subtypes using four biomarkers could provide clinically useful information of tumor biology and clinical behaviors, and could be used for determining treatment and surveillance strategies.

10 February 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SPSeho Park
Seho Park
Ja Seung KooJa Seung Koo
Ja Seung Koo
MKM. S. Kim
M. S. Kim
HPHyung Seok Park
Hyung Seok Park
JLJ. S. Lee
J. S. Lee
KLK. S. Lee
K. S. Lee
Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox’s models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.

23 November 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
BPB.-W. Park
B.-W. Park
JOJ.-W. Oh
J.-W. Oh
JKJ.-H. Kim
J.-H. Kim
SPSeho Park
Seho Park
KKK.-S. Kim
K.-S. Kim
KLK. S. Lee
K. S. Lee
Background: To investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)] and clinicopathological parameters and patient outcomes in breast cancer. Materials and methods: A total of 740 patients with stages I–III breast cancer had preoperative CA 15-3 and CEA concentrations measured. Univariate and multivariate analyses were used to investigate associations between marker concentration and clinicopathological parameters and patient outcomes. Results: Among 740 patients, elevated preoperative levels of CA 15-3 and CEA were identified in 92 (12.4%) and 79 (10.7%) patients, respectively. Tumor size (>5 cm), node metastases (≥4), and advanced stage (≥III) were associated with higher preoperative levels. Elevated CA 15-3 and CEA levels were associated with poor disease-free survival (DFS, P = 0.0014, P = 0.0001, respectively) and overall survival (OS, P = 0.018, P = 0.015) even in stage-matched analysis. Patients with normal levels of both CA 15-3 and CEA showed better DFS and OS than those with elevated group. In multivariate analysis, age (2 cm), node metastases, estrogen receptor expression, and elevated CA 15-3 and CEA preoperative values were independent prognostic factors for DFS. Conclusion: High preoperative CA 15-3 and CEA levels may reflect tumor burden and are associated with advanced disease and poor outcome. Measuring preoperative levels of CA 15-3 and CEA can be helpful for predicting outcomes.

12 May 2015 in Cancer
Verified
Journal Article
Open access
PDF file
JPJi‐Hye Park
Ji‐Hye Park
JLJunga Lee
Junga Lee
MOMinsuk Oh
Minsuk Oh
HPHyuna Park
Hyuna Park
JCJisuk Chae
Jisuk Chae
justin Y. Jeonjustin Y. Jeon
justin Y. Jeon
BACKGROUND: The purpose of the current study was to examine the effect of an oncologist's exercise recommendation with and without an exercise motivation package on the amount of exercise participation and quality of life (QOL) in survivors of breast and colorectal cancer.METHODS: A total of 162 survivors of early‐stage breast and colorectal cancer who completed primary and adjuvant treatments were recruited for the current study. Participants were randomly assigned into 1 of 3 groups: 1) control (59 patients); 2) those receiving an oncologist's exercise recommendation (53 patients); and 3) those receiving an oncologist's exercise recommendation with an exercise motivation package (50 patients). At baseline and after 4 weeks, the level of exercise participation and QOL were assessed.RESULTS: Of the 162 participants, 130 (80.2%) completed the trial. Intention‐to‐treat analysis indicated that participants who received an oncologist's exercise recommendation with an exercise motivation package significantly increased their level of exercise participation in terms of minutes (47.57 added minutes per week; 95% confidence interval, 9.62‐85.52 minutes [P =.022] vs control) and in Metabolic Equivalent of Task (MET)‐hours per week (4.14 additional MET‐hours per week; 95% confidence interval, 1.70‐6.58 MET‐hours [P =.004] vs control) compared with the control group. Participants who received only their oncologist's exercise recommendation did not increase their exercise participation level. Further analysis demonstrated that role functioning was significantly improved among participants who received an oncologist's exercise recommendation with an exercise motivation package.CONCLUSIONS: Providing an exercise motivation package in addition to the oncologist's exercise recommendation to increase the level of exercise among survivors of breast and colorectal cancer should be considered. Cancer 2015;121:2740‐2748. © 2015 American Cancer Society

1 July 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JMJong-Seok Moon
Jong-Seok Moon
HKHee Eun Kim
Hee Eun Kim
EKEunjin Koh
Eunjin Koh
SPSeho Park
Seho Park
WJWon-Ji Jin
Won-Ji Jin
KKKyung-Sup Kim
Kyung-Sup Kim
Krüppel-like factor 4 (KLF4) is a transcription factor that plays an important role in cell differentiation, proliferation, and survival, especially in the context of cancers. This study revealed that KLF4 activates glycolytic metabolism in breast cancer cells by up-regulating the platelet isoform of phosphofructokinase (PFKP). KLF4 activated the transcription of the PFKP gene by directly binding to the PFKP promoter. Whereas glucose uptake and lactate production were inhibited by the knockdown of KLF4, they were activated by the overexpression of KLF4. Unlike PFKP, the expressions of the other isoforms of phosphofructokinase and glycolytic genes were unaffected by KLF4. The human breast cancer tissues showed a close correlation between KLF4 and PFKP expression. This study also showed that PFKP plays a critical role in cell proliferation in breast cancer cells. In conclusion, it is suggested that KLF4 plays a role in maintenance of high glycolytic metabolism by transcriptional activation of the PFKP gene in breast cancer cells.